Skip to main content
Erschienen in: Diabetologia 3/2004

01.03.2004 | Article

Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells

verfasst von: Q. Wang, L. Li, E. Xu, V. Wong, C. Rhodes, P. L. Brubaker

Erschienen in: Diabetologia | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The incretin hormone glucagon-like peptide-1 augments islet cell mass in vivo by increasing proliferation and decreasing apoptosis of the beta cells. However, the signalling pathways that mediate these effects are mostly unknown. Using a clonal rat pancreatic beta cell line (INS-1), we examined the role of protein kinase B in mediating beta-cell growth and survival stimulated by glucagon-like peptide-1.

Methods

Immunoblot analysis was used to detect active (phospho-) and total protein kinase B. Proliferation was assessed using 3H-thymidine incorporation, while apoptosis was quantitated using 4′-6-diamidino-2-phenylindole staining and APO percentage apoptosis assay. Kinase-dead and wild-type protein kinase B was introduced into cells using adenoviral vectors.

Results

Glucagon-like peptide-1 rapidly activated protein kinase B in INS-1 cells (by 2.7±0.7-fold, p<0.05). This effect was completely abrogated by inhibition, with wortmannin, of the upstream activator of protein kinase B, phosphatidylinositol-3-kinase. Glucagon-like peptide-1 also stimulated INS-1 cell proliferation in a dose-dependent manner (by 1.8±0.5-fold at 10−7 mol/l, p<0.01), and inhibited staurosporine-induced apoptosis (by 69±12%, p<0.05). Both of these effects were also prevented by wortmannin treatment. Ablation of protein kinase B by adenovirus-mediated overexpression of the kinase-dead form of protein kinase Bα prevented protein kinase B phosphorylation and completely abrogated both cellular proliferation (p<0.05) and protection from drug-induced cellular death (p<0.01) induced by glucagon-like peptide-1.

Conclusions/interpretation

These results identify protein kinase B as an essential mediator linking the glucagon-like peptide-1 signal to the intracellular machinery that modulates beta-cell growth and survival.
Literatur
1.
Zurück zum Zitat Drucker DJ (2002) Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531–544CrossRefPubMed Drucker DJ (2002) Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531–544CrossRefPubMed
2.
Zurück zum Zitat Nauck MA, Holst JJ, Willms B, Schmiegel W (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2 diabetes. Exp Clin Endocrinol Diabetes 105:187–195CrossRefPubMed Nauck MA, Holst JJ, Willms B, Schmiegel W (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2 diabetes. Exp Clin Endocrinol Diabetes 105:187–195CrossRefPubMed
3.
Zurück zum Zitat Nauck MA, Wollschlager D, Werner J et al. (1996) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia 39:1546–1553CrossRefPubMed Nauck MA, Wollschlager D, Werner J et al. (1996) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia 39:1546–1553CrossRefPubMed
4.
Zurück zum Zitat Ritzel R, Orskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38:720–725CrossRefPubMed Ritzel R, Orskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38:720–725CrossRefPubMed
5.
Zurück zum Zitat Holz GG 4th, Kuhtreiber WM, Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37). Nature 361:362–365CrossRefPubMedPubMedCentral Holz GG 4th, Kuhtreiber WM, Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37). Nature 361:362–365CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Komatsu R, Matsuyama T, Namba M et al. (1989) Glucagonostatic and insulinotropic action of glucagon-like peptide I-(7–36)-amide. Diabetes 38:902–905CrossRefPubMed Komatsu R, Matsuyama T, Namba M et al. (1989) Glucagonostatic and insulinotropic action of glucagon-like peptide I-(7–36)-amide. Diabetes 38:902–905CrossRefPubMed
7.
Zurück zum Zitat Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327–332PubMed Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327–332PubMed
8.
Zurück zum Zitat Schirra J, Kuwert P, Wank U et al. (1997) Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 109:84–97PubMed Schirra J, Kuwert P, Wank U et al. (1997) Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 109:84–97PubMed
9.
Zurück zum Zitat Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N (2000) The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6:802–807CrossRefPubMed Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N (2000) The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6:802–807CrossRefPubMed
10.
Zurück zum Zitat Toft-Nielsen MB, Madsbad S, Holst JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137–1143CrossRefPubMed Toft-Nielsen MB, Madsbad S, Holst JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137–1143CrossRefPubMed
11.
Zurück zum Zitat Sandhu H, Wiesenthal S, MacDonald PE et al. (1999) Glucagon-like peptide-1 increases insulin sensitivity in depancreatized dogs. Diabetes 48:1045–1053CrossRefPubMed Sandhu H, Wiesenthal S, MacDonald PE et al. (1999) Glucagon-like peptide-1 increases insulin sensitivity in depancreatized dogs. Diabetes 48:1045–1053CrossRefPubMed
12.
Zurück zum Zitat Prigeon RL, Quddusi S, Paty B, D’Alessio DA (2003) Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701–E707CrossRefPubMed Prigeon RL, Quddusi S, Paty B, D’Alessio DA (2003) Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701–E707CrossRefPubMed
13.
Zurück zum Zitat Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824–830CrossRefPubMed Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824–830CrossRefPubMed
14.
Zurück zum Zitat Thum A, Hupe-Sodmann K, Goke R, Voigt K, Goke B, McGregor GP (2002) Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 110:113–118CrossRefPubMed Thum A, Hupe-Sodmann K, Goke R, Voigt K, Goke B, McGregor GP (2002) Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 110:113–118CrossRefPubMed
15.
Zurück zum Zitat Goke R, Fehmann HC, Linn T et al. (1993) Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650–19655PubMed Goke R, Fehmann HC, Linn T et al. (1993) Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650–19655PubMed
16.
Zurück zum Zitat Edvell A, Lindstrom P (1999) Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology 140:778–783 Edvell A, Lindstrom P (1999) Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology 140:778–783
17.
Zurück zum Zitat Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270–2276CrossRefPubMed Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270–2276CrossRefPubMed
18.
Zurück zum Zitat Stoffers DA, Kieffer TJ, Hussain MA et al. (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741–748CrossRefPubMed Stoffers DA, Kieffer TJ, Hussain MA et al. (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741–748CrossRefPubMed
19.
Zurück zum Zitat Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471–478CrossRefPubMed Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471–478CrossRefPubMed
20.
Zurück zum Zitat Wang Q, Brubaker PL (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263–1273CrossRefPubMed Wang Q, Brubaker PL (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263–1273CrossRefPubMed
21.
Zurück zum Zitat Kandel ES, Hay N (1999) The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253:210–229CrossRefPubMed Kandel ES, Hay N (1999) The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253:210–229CrossRefPubMed
22.
Zurück zum Zitat Hajduch E, Litherland GJ, Hundal HS (2001) Protein kinase B (PKB/Akt)—a key regulator of glucose transport? FEBS Lett 492:199–203CrossRefPubMed Hajduch E, Litherland GJ, Hundal HS (2001) Protein kinase B (PKB/Akt)—a key regulator of glucose transport? FEBS Lett 492:199–203CrossRefPubMed
23.
Zurück zum Zitat Scheid MP, Woodgett JR (2001) PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2:760–768CrossRefPubMed Scheid MP, Woodgett JR (2001) PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2:760–768CrossRefPubMed
24.
Zurück zum Zitat Holst LS, Mulder H, Manganiella V et al. (1998) Protein kinase B is expressed in pancreatic beta cells and activated upon stimulation with insulin-like growth factor I. Biochem Biophys Res Commun 250:181–186CrossRefPubMed Holst LS, Mulder H, Manganiella V et al. (1998) Protein kinase B is expressed in pancreatic beta cells and activated upon stimulation with insulin-like growth factor I. Biochem Biophys Res Commun 250:181–186CrossRefPubMed
25.
Zurück zum Zitat Aikin R, Rosenberg L, Maysinger D (2000) Phosphatidylinositol 3-kinase signaling to Akt mediates survival in isolated canine islets of Langerhans. Biochem Biophys Res Commun 277:455–461CrossRefPubMed Aikin R, Rosenberg L, Maysinger D (2000) Phosphatidylinositol 3-kinase signaling to Akt mediates survival in isolated canine islets of Langerhans. Biochem Biophys Res Commun 277:455–461CrossRefPubMed
26.
Zurück zum Zitat Sherwood DJ, Dufresne SD, Markuns JF et al. (1999) Differential regulation of MAP kinase, p70(S6K), and Akt by contraction and insulin in rat skeletal muscle. Am J Physiol Endocrinol Metab 276:E870–E878 Sherwood DJ, Dufresne SD, Markuns JF et al. (1999) Differential regulation of MAP kinase, p70(S6K), and Akt by contraction and insulin in rat skeletal muscle. Am J Physiol Endocrinol Metab 276:E870–E878
27.
Zurück zum Zitat Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA (2001) Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 108:1631–1638CrossRefPubMedPubMedCentral Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA (2001) Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 108:1631–1638CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Tuttle RL, Gill NS, Pugh W et al. (2001) Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med 7:1133–1137CrossRefPubMed Tuttle RL, Gill NS, Pugh W et al. (2001) Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med 7:1133–1137CrossRefPubMed
29.
Zurück zum Zitat Dickson LM, Lingohr MK, McCuaig J et al. (2001) Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). J Biol Chem 276:21110–21120CrossRefPubMed Dickson LM, Lingohr MK, McCuaig J et al. (2001) Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). J Biol Chem 276:21110–21120CrossRefPubMed
30.
Zurück zum Zitat Wrede CE, Dickson LM, Lingohr MK, Briaud I, Rhodes CJ (2002) Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1). J Biol Chem 277:49676–49684CrossRefPubMed Wrede CE, Dickson LM, Lingohr MK, Briaud I, Rhodes CJ (2002) Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1). J Biol Chem 277:49676–49684CrossRefPubMed
31.
Zurück zum Zitat Buteau J, Roduit R, Susini S, Prentki M (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42:856–864CrossRefPubMed Buteau J, Roduit R, Susini S, Prentki M (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42:856–864CrossRefPubMed
32.
Zurück zum Zitat Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M (2001) Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 50:2237–2243CrossRefPubMed Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M (2001) Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 50:2237–2243CrossRefPubMed
33.
Zurück zum Zitat Buteau J, Foisy S, Joly E, Prentki M (2003) Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52:124–132CrossRefPubMed Buteau J, Foisy S, Joly E, Prentki M (2003) Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52:124–132CrossRefPubMed
34.
Zurück zum Zitat Trumper K, Trumper A, Trusheim H, Arnold R, Goke B, Horsch D (2000) Integrative mitogenic role of protein kinase B/Akt in beta-cells. Ann NY Acad Sci 921:242–250CrossRefPubMed Trumper K, Trumper A, Trusheim H, Arnold R, Goke B, Horsch D (2000) Integrative mitogenic role of protein kinase B/Akt in beta-cells. Ann NY Acad Sci 921:242–250CrossRefPubMed
35.
Zurück zum Zitat Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB (1992) Establishment of 2-mercaptoethanol-dependent differentiated insulin- secreting cell lines. Endocrinology 130:167–178PubMed Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB (1992) Establishment of 2-mercaptoethanol-dependent differentiated insulin- secreting cell lines. Endocrinology 130:167–178PubMed
36.
Zurück zum Zitat Godard T, Deslandes E, Lebailly P et al. (1999) Comet assay and DNA flow cytometry analysis of staurosporine-induced apoptosis. Cytometry 36:117–122CrossRefPubMed Godard T, Deslandes E, Lebailly P et al. (1999) Comet assay and DNA flow cytometry analysis of staurosporine-induced apoptosis. Cytometry 36:117–122CrossRefPubMed
37.
Zurück zum Zitat Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D (2001) Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15:1559–1570PubMed Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D (2001) Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15:1559–1570PubMed
38.
Zurück zum Zitat Cho H, Mu J, Kim JK et al. (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728–1731CrossRefPubMed Cho H, Mu J, Kim JK et al. (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728–1731CrossRefPubMed
39.
Zurück zum Zitat Garofalo RS, Orena SJ, Rafidi K et al. (2003) Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 112:197–208CrossRefPubMedPubMedCentral Garofalo RS, Orena SJ, Rafidi K et al. (2003) Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 112:197–208CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Trumper A, Trumper K, Horsch D (2002) Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 174:233–246CrossRefPubMed Trumper A, Trumper K, Horsch D (2002) Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 174:233–246CrossRefPubMed
41.
Zurück zum Zitat Brubaker PL, Drucker DJ (2002) Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1 and GLP-2 receptors. Receptors Channels 8:179–188CrossRefPubMed Brubaker PL, Drucker DJ (2002) Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1 and GLP-2 receptors. Receptors Channels 8:179–188CrossRefPubMed
42.
Zurück zum Zitat Xiao Q, Giguere J, Parisien M et al. (2001) Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40:2860–2869CrossRefPubMed Xiao Q, Giguere J, Parisien M et al. (2001) Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40:2860–2869CrossRefPubMed
43.
Zurück zum Zitat Ehses JA, Pelech SL, Pederson RA, McIntosh CH (2002) Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2- ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277:37088–37097CrossRefPubMed Ehses JA, Pelech SL, Pederson RA, McIntosh CH (2002) Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2- ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277:37088–37097CrossRefPubMed
44.
Zurück zum Zitat Yusta B, Estall J, Drucker DJ (2002) Glucagon-like peptide-2 receptor activation engages Bad and glucagon synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem 277:24896–24906CrossRefPubMed Yusta B, Estall J, Drucker DJ (2002) Glucagon-like peptide-2 receptor activation engages Bad and glucagon synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem 277:24896–24906CrossRefPubMed
45.
Zurück zum Zitat Chen HL, Demiralp B, Schneider A et al. (2002) Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 277:19374–19381CrossRefPubMed Chen HL, Demiralp B, Schneider A et al. (2002) Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 277:19374–19381CrossRefPubMed
46.
Zurück zum Zitat Sasaki T, Irie-Sasaki J, Jones RG et al. (2000) Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287:1040–1046CrossRefPubMed Sasaki T, Irie-Sasaki J, Jones RG et al. (2000) Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287:1040–1046CrossRefPubMed
47.
Zurück zum Zitat Mei FC, Qiao J, Tsygankova OM, Meinkoth JL, Quilliam LA, Cheng X (2002) Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. J Biol Chem 277:11497–11504CrossRefPubMed Mei FC, Qiao J, Tsygankova OM, Meinkoth JL, Quilliam LA, Cheng X (2002) Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. J Biol Chem 277:11497–11504CrossRefPubMed
48.
Zurück zum Zitat Kang G, Chepurny OG, Holz GG (2001) cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol 536:375–385CrossRefPubMedPubMedCentral Kang G, Chepurny OG, Holz GG (2001) cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol 536:375–385CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB (2000) Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49:424–430CrossRefPubMed Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB (2000) Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49:424–430CrossRefPubMed
50.
Zurück zum Zitat Baggio L, Adatia FA, Bock T, Brubaker PL, Drucker DJ (2000) Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 275:34471–34477CrossRefPubMed Baggio L, Adatia FA, Bock T, Brubaker PL, Drucker DJ (2000) Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 275:34471–34477CrossRefPubMed
51.
Zurück zum Zitat Ling Z, Wu D, Zambre Y et al. (2001) Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438:382–387CrossRefPubMed Ling Z, Wu D, Zambre Y et al. (2001) Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438:382–387CrossRefPubMed
52.
Zurück zum Zitat De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA (2003) Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52:365–371CrossRef De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA (2003) Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52:365–371CrossRef
Metadaten
Titel
Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells
verfasst von
Q. Wang
L. Li
E. Xu
V. Wong
C. Rhodes
P. L. Brubaker
Publikationsdatum
01.03.2004
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 3/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1327-5

Weitere Artikel der Ausgabe 3/2004

Diabetologia 3/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.